Answers are grounded in this paper and cite their sources.
Novel research demonstrates that PINK1 deficiency worsens bone loss in older populations, suggesting new treatment targets.
Age-related bone loss contributes to frailty, fractures, and increased mortality in the elderly, yet current osteoporosis treatments have limited long-term efficacy. Mitochondrial dysfunction is a hallmark of skeletal aging, but its role in mesenchymal lineage commitment remains unclear. Here, we investigated PTEN-induced kinase 1 (PINK1), a serine/threonine kinase essential for mitophagy, in regulating bone mass and adipogenic differentiation during aging. Using Pink1 knockout ( Pink1 –/– ) mice, we found that Pink1 deficiency exacerbated trabecular bone loss and promoted adipocyte hypertrophy in white adipose tissue. Calvarial pre-osteoblasts from Pink1 –/– mice displayed impaired osteogenic differentiation and increased adipogenesis, evidenced by reduced alkaline phosphatase (ALP) activity, mineralization, and osteogenic gene expression, alongside elevated lipid accumulation. In vitro , siRNA-mediated Pink1 knockdown in 3T3-L1 cells triggered adipogenic, inflammatory, and oxidative stress responses, while suppressing mitochondrial function and respiration. Collectively, these findings reveal that PINK1 preserves skeletal integrity by maintaining mitochondrial homeostasis and restraining stress-induced adipogenic reprogramming. Our study identifies the PINK1–mitophagy axis as a potential therapeutic target for preventing age-related bone loss and preserving bone health.
No takes yet. Share an insight, caveat, or question.
Sung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: